Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 9/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | CCNK | O75909 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911268 | 0.89 | MAPK3 (0.72) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL9911273 | 0.83 | MAPK3 (0.53) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL9911272 | 0.81 | LRRK2 (0.52) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL9911274 | 0.81 | MAPK3 (0.58) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL9911258 | 0.81 | MAPK3 (0.49) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL9911271 | 0.80 | MAPK3 (0.50) | MAPK3LRRK2JAK2 | |
| SCHEMBL9911269 | 0.79 | MAPK3 (0.52) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL10042753 | 0.76 | MAPK3 (0.44) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL19175634 | 0.76 | MAPK3 (0.81) | MAPK3CCNA2CDK2CCNKCDK9 | |
| SCHEMBL10042754 | 0.76 | LRRK2 (0.61) | MAPK3CCNA2CDK2CCNKCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | MAPK3 978/4885CCNA2 2211/4885CDK2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.